{"id":"93cf920f-879a-58f5-a0f4-83a8d66de28e","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:b3-cons-sarm-adpr-nam","predicate":"hydrolyzes","statement":"Purified human SARM1 TIR domain cleaved NAD+, producing ADP-ribose and nicotinamide as major products.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"3cd2db48-96a6-55a8-adb0-8ac8d325495b","mechanism_event_label":"SARM1 contains a catalytic domain that breaks NAD.","subject":{"id":"34873c2d-4607-5dc7-8cd5-d443adb3365d","slug":"sarm1-tir-domain","display_name":"Human SARM1 TIR-domain construct","entity_type_key":"protein_state"},"object":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"3cd2db48-96a6-55a8-adb0-8ac8d325495b","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:b3-cons-sarm-adpr-nam-event","event_type":"biochemical_relationship","label":"SARM1 contains a catalytic domain that breaks NAD.","description":"Purified human SARM1 TIR domain cleaved NAD+, producing ADP-ribose and nicotinamide as major products.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"34873c2d-4607-5dc7-8cd5-d443adb3365d","slug":"sarm1-tir-domain","display_name":"Human SARM1 TIR-domain construct","entity_type_key":"protein_state"},"role":"enzyme","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"substrate","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6207ad52-d36c-5800-8e6e-effe789ab038","slug":"adp-ribose","display_name":"ADP-ribose","entity_type_key":"small_molecule"},"role":"product","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"role":"coproduct","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"false","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-consumption-sources/sarm2017.txt\", \"locator\": \"Full text, normalized paragraph 24\", \"start_char\": 15550, \"end_char\": 16946, \"file_sha256\": \"fc30de231911f5c30425173d684495e62c725ba27c78d44592e6bc68433ef545\", \"text_sha256\": \"9a9b91a772186c34d8b6305a04bbcf6d3acc40b0448e6f478811527c5174981e\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Purified human SARM1 TIR domain; HPLC and LC-MS/MS","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"NAD+ incubation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Purified engineered TIR fragment rather than basal activity of intact full-length SARM1; no dietary dose inference.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"SARM1 contains a catalytic domain that breaks NAD.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b3-cons-sarm2017] The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. (2017). https://pubmed.ncbi.nlm.nih.gov/28334607/ DOI: 10.1016/j.neuron.2017.02.022","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Cell-free preparation","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"5ddb6a32-f905-5d5a-8617-31073b0717db","evidence_kind":"source_excerpt","locator":"Lines 677-689","start_line":677,"end_line":689,"excerpt":"### b3-cons-sarm-adpr-nam\nPurified human SARM1 TIR domain cleaved NAD+, producing ADP-ribose and nicotinamide as major products.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: SARM1 contains a catalytic domain that breaks NAD.\norganism: Human\ntissue_or_cell_type: Cell-free preparation\nexperimental_model: Purified human SARM1 TIR domain; HPLC and LC-MS/MS\nlimitations: Purified engineered TIR fragment rather than basal activity of intact full-length SARM1; no dietary dose inference.\nexposure: NAD+ incubation\ncross_nutrient: false\nevidence_span: {\"source_cache\": \"artifacts/niacin-consumption-sources/sarm2017.txt\", \"locator\": \"Full text, normalized paragraph 24\", \"start_char\": 15550, \"end_char\": 16946, \"file_sha256\": \"fc30de231911f5c30425173d684495e62c725ba27c78d44592e6bc68433ef545\", \"text_sha256\": \"9a9b91a772186c34d8b6305a04bbcf6d3acc40b0448e6f478811527c5174981e\"}\n[b3-cons-sarm2017] The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. (2017). https://pubmed.ncbi.nlm.nih.gov/28334607/ DOI: 10.1016/j.neuron.2017.02.022","model_system":"Purified human SARM1 TIR domain; HPLC and LC-MS/MS","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b3-cons-sarm2017] The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. (2017). https://pubmed.ncbi.nlm.nih.gov/28334607/ DOI: 10.1016/j.neuron.2017.02.022","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}